The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.
all phototypes
only one of the following pigmentary conditions on the face: epidermal or mixed, mild to moderate melasma; mild to moderate acne-induced PIHP; solar lentigo
female patient of childbearing potential must use one of the reliable methods of contraception and agree not to change it during the study
patient agreeing not to be exposed to ultraviolet radiation (UV), natural (sun) or artificial (tanning salon), during the study
female patient who gave birth less than 3 months prior to Day 0, who is pregnant, breast-feeding or who plans to become pregnant during the study
male patient with beard or facial hair, which would interfere with clinical evaluation or clinical procedure baseline)
patient with any inflammatory dermatosis of the face such as seborrheic dermatitis, rosacea etc.
severe melasma, dermal melasma